Merck wraps up $1.8bn acquisition of Pandion Therapeutics

Merck wraps up $1.8bn acquisition of Pandion Therapeutics

(adsbygoogle = window.adsbygoogle || []).push({}); Merck has wrapped up its previously announced $1.85 billion acquisition of Massachusetts-based clinical-stage biotech company Pandion Therapeutics. The pharma giant said that it had successfully completed the cash tender offer, via a subsidiary, for all of the outstanding shares of Pandion More...

by businessnewstoday | Published 5 hours ago
Sterling Pharma Solutions acquires antibody drug conjugate manufacturer ADC Bio
By businessnewstoday On Sunday, April 11th, 2021
0 Comments

Sterling Pharma acquires antibody drug conjugate manufacturer ADC Bio

Sterling Pharma Solutions has acquired ADC Biotechnology (ADC Bio), a bioconjugation development services business based in the UK, which specializes in antibody drug conjugates (ADCs). The UK-based contract development More...

Dr. Reddy's Laboratories launches Sapropterin dihydrochloride powder in US
By businessnewstoday On Thursday, April 8th, 2021
0 Comments

Dr. Reddy’s Laboratories launches Sapropterin dihydrochloride powder in US

Dr. Reddy’s Laboratories has launched Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a generic of BioMarin’s Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, approved by More...

Gan & Lee gets EMA orphan drug status for GLR2007 in glioma
By businessnewstoday On Tuesday, April 6th, 2021
0 Comments

Gan & Lee gets EMA orphan drug status for GLR2007 in glioma

Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type of tumor found in the brain and spinal cord. The Chinese More...

Bioniz Therapeutics gets EC orphan drug status for BNZ-1 for cutaneous T-cell lymphoma.
By businessnewstoday On Tuesday, April 6th, 2021
0 Comments

Bioniz Therapeutics gets EC orphan drug status for BNZ-1 for CTCL

Bioniz Therapeutics has secured orphan drug designation for BNZ-1 from the European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Previously, BNZ-1 was given More...

Sound Pharmaceuticals gets NIH grant for testing Covid-19 candidate SPI-1005 in phase 2 trials.
By businessnewstoday On Tuesday, April 6th, 2021
0 Comments

Sound Pharmaceuticals gets NIH grant for Covid-19 candidate SPI-1005

Sound Pharmaceuticals has secured a grant of $3.1 million for supporting the evaluation of its COVID-19 treatment candidate SPI-1005 in two phase 2 clinical trials from the National Center for Advancing Translational More...

Grifols phase 3 Covid-19 trial of hyperimmune globulins fails to meet objective
By businessnewstoday On Saturday, April 3rd, 2021
0 Comments

Grifols phase 3 Covid-19 trial of hyperimmune globulins fails to meet objective

Spanish pharma company Grifols said that the phase 3 ITAC clinical trial assessing hyperimmune globulins as a treatment for patients hospitalized with Covid-19 has failed to meet its primary endpoints. ITAC expands More...

Cellphire Therapeutics raises $15m in Series A funding round
By businessnewstoday On Saturday, April 3rd, 2021
0 Comments

Cellphire Therapeutics raises $15m in Series A funding round

Cellphire Therapeutics, a Maryland-based biotech company focused on the long-term stabilization and storage of platelets, has raised $15 million in a Series A funding round. The financing round was led by Simcah More...

Amgen acquisition of Rodeo Therapeutics
By businessnewstoday On Wednesday, March 31st, 2021
0 Comments

Amgen to acquire Rodeo Therapeutics in $721m worth deal

Amgen has agreed to acquire Rodeo Therapeutics, a Seattle-based biopharma company, in a deal worth up to $721 million. Rodeo Therapeutics is engaged in developing small-molecule therapies designed for promoting More...

Pyxis Oncology raises $152m in Series B round for cancer therapies
By businessnewstoday On Tuesday, March 30th, 2021
0 Comments

Pyxis Oncology raises $152m in Series B round for cancer therapies

Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, More...